The International Society of Urological Pathology/Vancouver Classification of Renal Neoplasia: New entities of adult renal cell carcinoma  by Pan, Chin-Chen
lable at ScienceDirect
Urological Science 26 (2015) 77e80Contents lists avaiUrological Science
journal homepage: www.urol-sci .comReview articleThe International Society of Urological Pathology/Vancouver
Classiﬁcation of Renal Neoplasia: New entities of adult renal
cell carcinoma*Chin-Chen Pan*
Departments of Pathology and Laboratory Medicine, Taipei Veterans General Hospital Taipei, Taiwana r t i c l e i n f oArticle history:
Received 23 January 2015
Received in revised form
7 April 2015
Accepted 14 April 2015
Available online 19 May 2015
Keywords:
International Society of Urological Pathol-
ogy Classiﬁcation
renal cell carcinoma1. Introduction
During the past decade following the publication of the World
Health Organization (WHO) classiﬁcation of renal tumors in 2004,1
urologists and pathologists have encountered a surge of new en-
tities of renal neoplasms. Scrutiny of subtle histologic features,
detailed marker analyses, as well as advances in novel molecular
and cytogenetic techniques all facilitate to characterize these en-
tities that were either inadequately deﬁned or categorized as other
diseases in the past.
The International Society of Urological Pathology (ISUP) is the
international professional organization dedicated to the subspe-
cialty of urological pathology. In 2011, the Society undertook to
review all aspects of the pathology of adult renal malignancy
through an international consensus conference held in 2012 in
Vancouver, Canada.2 The classiﬁcation working group of the ISUP
consensus conference on renal neoplasia was entrusted with the
responsibility of reviewing available literature and making* Department of Pathology, Taipei Veterans General Hospital, Number 201, Shi-
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to the current renal tumor classiﬁcation system. On the basis of the
above inputs, there was a consensus that ﬁve entities should be
recognized as new distinct epithelial tumors within the classiﬁca-
tion system.3 There were a number of new concepts and suggested
modiﬁcations to the existing WHO 2004 categories. The new clas-
siﬁcation is to be referred to as the ISUP/Vancouver Classiﬁcation of
Renal Neoplasia and is likely to be adopted in the next edition of
WHO classiﬁcations.
2. Proposed new epithelial neoplasms
This review brieﬂy summarizes the rationale and salient fea-
tures of the ﬁve newly proposed entities.
2.1. Tubulocystic carcinoma
Tubulocystic carcinoma was ﬁrst described in 1955 by Masson,
who designated the lesion “Bellinian epithelioma” because he
regarded it as a neoplasm originating in the collecting ducts of
Bellini. Later the tumor was designated as “low-grade mucinous
tubulocystic renal carcinoma of possible collecting duct origin”.4
With more cases showing similarly clinical and pathological fea-
tures, the name of the neoplasm was changed to “tubulocystic
carcinoma” to denote the speciﬁc morphology.5,6
Diagnosis is rendered chieﬂy on the basis of distinct morpho-
logic characteristics. Grossly, the tumors may have a “bubblewrap”,
‘‘Swiss cheese’’, or spongy appearance of the cut surface. Micro-
scopically, the tumor is composed of tubules and cystic structures
of markedly variable size, separated by delicate septa. Tubules are
lined by a single layer of cuboidal epithelial cells with eosinophilic
cytoplasm, round nuclei, and characteristically prominent nucleoli
(grade 3) in most cases (Fig. 1).
Immunohistochemistry does not play a crucial role in differen-
tial diagnosis. Tubulocystic carcinomas express alpha-methylacyl-
CoA racemase and CD10. The tumor cells stain positively for cyto-
keratins CK8, CK18, and CK19 and less frequently for CK7. A pro-
portion of cases stain positively for high-molecular weight keratin
(34bE12) and carbonic anhydrase IX.an LLC. Open access under CC BY-NC-ND license.
Fig. 1. Tubulocystic carcinoma, tubulocystic structures lined with cuboidal cells (he-
matoxylin-eosin, 200).
Fig. 2. Acquired cystic disease-associated renal cell carcinoma, cribriform pattern
consisting of polygonal tumor cells with abundant eosinophilic cytoplasm (hematox-
ylin-eosin, 200).
Fig. 3. Clear papillary renal cell carcinoma, clear cells arranged in branching acinar and
papillary pattern (hematoxylin-eosin, 200).
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no overlapping with clear cell, chromophobe, and collecting duct
renal cell carcinoma (RCC). A relationship with papillary RCC has
been claimed,7 especially for the frequent gains on chromosome 7
and chromosome 17, and loss of Y chromosome, which are the
hallmarks of papillary RCC. Coexisting tubulocystic carcinoma and
papillary RCC have been reported, and a tubulocystic pattern is oc-
casionally observed in otherwise typical papillary RCC.Nevertheless,
the term tubulocystic carcinoma should be restricted to those tu-
mors that display typical macroscopic and microscopic appearance.
The term should not be used in situations where there is a tubulo-
cystic pattern admixed with the usual elements of papillary RCC.
Tubulocystic carcinomas tend to present in low stage and
behave indolently. However, sarcomatoid change, as well as local
recurrence, distant metastases to lymph nodes, lung, and brain
have been reported.5e7
2.2. Acquired cystic disease-associated RCC
Acquired cystic disease (ACD)-associated RCCs are observed
exclusively in the background of ACD of the kidney. It has not been
reported in noncystic end-stage renal disease (ESRD) and patients
without ESRD.8 It may be detected in patients with clinically renal
masses, but more often present as an incidental ﬁnding in ne-
phrectomies performed for other nontumorous situations. Grossly,
they are usually small and may be found within cysts. Multifocality
and bilaterality are not uncommon.
Histologically, ACD-associated RCCs show a spectrum of
morphologic features, but the presence of eosinophilic cells with
Furman grade 3 nuclei and cribriform, as well as tubulocystic pat-
terns, are consistent ﬁndings (Fig. 2). Areas with papillary, alveolar,
solid, or diffuse patterns may also be seen. Another peculiar feature
of ACD-associated RCC is the presence of intratumoral oxalate
crystals in most, but not all, tumors.9,10
The “atypical cysts” in ACD are most likely precursors of ACD-
associated RCC. Histologically, the lining epithelium of “atypical
cysts” often have eosinophilic cytoplasm and large nucleoli similar
to that of ACD-associated RCC. Occasionally, there are multilayering
of the cystic epitheliumwith formation of papillary tufts or nodular
lesions.10
A speciﬁc immunohistochemical proﬁle is not required to
conﬁrm this diagnosis. ACD-associated RCCs are diffusely immu-
noreactive for alpha-methylacyl-CoA racemase, CD10, RCC Marker,and glutathione S-transferase-alpha. The tumors usually do not
express or only focally express CK7.10
ACD-RCC has a relatively good prognosis, becausemost cases are
diagnosed early in patients on long-term follow-up for chronic
renal disease. However, sarcomatoid or rhabdoid features have
been reported, and a few cases can metastasize.8,112.3. Clear cell papillary RCC
Clear cell papillary RCC was ﬁrst described by Tickoo et al8 in
their report of a systemic survey of the tumors associated with
ESRD. Unlike ACD-associated RCC, clear cell papillary RCCs also
arise in the kidneys of noncystic ESRD and the normal kidneys of
the general population.12,13 Tumors with similar morphology and
immunoproﬁle described under different appellations such as renal
angiomyoadenomatous tumor14 and RCC with diffuse CK7 immu-
noreactivity15 are now interpreted by consensus as belonging to the
morphologic spectrum of clear cell papillary RCC.
The tumors are mostly well circumscribed and enveloped by a
thin capsule. Microscopically, the tumor shows a mixed papilllary,
solid-acinar, tubular, and microcystic pattern. Irrespective of the
architecture, the tumors were almost entirely composed of cells
with clear cytoplasm (Fig. 3). One characteristic feature is the linear
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middle or the apex of the cells (reverse polarity). It should be noted
that clear cell papillary RCC is a distinct entity from either clear cell
RCC and papillary RCC. The tumor is not a hybrid or composite
tumor made of clear cell RCC and papillary RCC.
In contrast to other morphologic types of RCC that do not
require immunochemistry for diagnosis, a proper immunoproﬁle,
namely, the diffuse immunoreactivity for CK7, which is almost al-
ways in 100% of the tumor cells, is a prerequisite to establish the
diagnosis of clear cell papillary RCC. Tumors morphologically
resembling clear cell papillary RCC yet lack typical CK7 immuno-
reactivity cannot be conﬁdently diagnosed as such. Tumor cells also
express carbonic anhydrase IX diffusely in a membranous cup-
shaped distribution. Immunostains for alpha-methylacyl-CoA
racemase, CD10, and RCC marker are mostly negative.
The small number of published cases with limited follow-up
data indicates that these are neoplasms with indolent clinical
behavior. Metastases have not been reported to date.2.4. t(6;11) RCC
The 2004 WHO classiﬁcation has already included Xp11 trans-
location carcinoma. While Xp11 translocation RCCs consistently
involve the fusion of TFE3, t(6,11) RCCs involve transcription factor
EB (TFEB), which is another member of the MiT subfamily of
transcription factors. t(6,11) RCCs are characterized by
t(6;11)(p21;q12), which results in an Alpha-TFEB gene fusion.7,16
This neoplasm typically demonstrates distinctive biphasic
morphology, comprising larger and smaller epithelioid cells, with
the latter often clustered around basement membrane material
(Fig. 4). The tumors consistently express melanocytic markers such
as HMB-45 and Melan-A, but are either negative or only focally
positive for epithelial markers such as cytokeratins. The Alpha-TFEB
gene fusion results in overexpression of native TFEB. Nuclear la-
beling for TFEB protein by immunohistochemistry is thus a sensi-
tive and speciﬁc assay for diagnosis. Virtually all cases express
cathepsin-K, which is also expressed in a subset of Xp11 trans-
location RCC, but not in other common RCC subtypes.17 The ma-
jority of cases express PAX8, supporting renal tubular
differentiation.
According to the clinicopathologic, immunohistochemical, and
genetic similarities to the Xp11 translocation RCC, there has been a
consensus that the t(6:11) RCC should be included with the former
under the category of MiT translocation RCC.Fig. 4. t(6,11) renal cell carcinoma, trabeculae of clear cells and clusters of small dark
cells admixed with basement-like material. (hematoxylin-eosin, 200).Since the available data about this neoplasm have been limited,
the clinicopathologic spectrum remains to be elucidated. Some
cases metastasized and caused death of the patient.18,192.5. Hereditary leiomyomatosis RCC syndromeeassociated RCC
Hereditary leiomyomatosis RCC syndrome is autosomal domi-
nant and is associated with germline mutations in the fumarate
hydratase gene located at chromosome 1q42. The main features of
this syndrome are frequent and multiple cutaneous and uterine
leiomyomas, which are difﬁcult to manage and require hysterec-
tomy before the age of 30 years in around half of patients. The RCCs
associated with this syndrome affect approximately one third of
patients. These syndromic neoplasms are solitary but are highly
aggressive, usually presenting in advanced stages and are lethal.20
Hereditary leiomyomatosis RCCeassociated RCC (HLRCC) was
listed in the 2004 WHO classiﬁcation under the category of familial
RCC.1 The tumor was suggested as a subtype of type 2 papillary RCC
at that time. However, the tumor manifests several features distinct
from typical papillary RCC, such as prominent eosinophilic nucleoli
with a clear halo, mimicking cytomegalovirus inclusions in both the
RCC and leiomyomas. Architecturally, HLRCCs frequently have
papillary architecture, but other architectures such as cribriform
and solid may also be present.21
HLRCCs and leiomyomas in the syndrome demonstrate biallelic
inactivation of fumarate hydratase, with germline mutations in one
allele and loss of the second allele. Although experience with
HLRCC is largely limited to the National Institutes of Health Group,
there is a consensus to recognize HLRCC as a distinctive entity.
Given the aggressive behavior of the tumor, patients with this
syndrome should be followed more closely to eradicate the renal
masses even when they are small.3. Provisional new tumor entities
Aside from the abovementioned new entities, there are three
rare RCCs that are considered as emerging or provisional new en-
tities in the ISUP conference. Thyroid-like follicular RCC is charac-
terized by macrofollicular and/or microfollicular architecture
associated with dense colloid-like material resembling follicular
neoplasm of thyroid (Fig. 5). However, thyroid-like follicular RCCs
do not express thyroid markers including thyroid transcription
factor-1 and thyroglobulin.22 On the contrary, papillary RCCs orFig. 5. Thyroid-like follicular renal cell carcinoma, macrofollicular, and microfollicular
architecture containing dense colloid-like material (hematoxylin-eosin, 200).
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focal areas also.
Succinate dehydrogenase B (SDHB) deﬁciencyeassociated RCC is
a renal neoplasm associated with pheochromocytoma/para-
ganglioma syndrome type 4.23 Loss of the SDHB protein using
immunohistochemistry is reported to be a sensitive and speciﬁc
marker for these neoplasms. Morphologically, these neoplasms are
usually unencapsulated and composed of compact nests of eosin-
ophilic polygonal cells which may have vacuolated cytoplasm or
distinctive pale eosinophilic cytoplasmic inclusions corresponding
to giant mitochondria upon ultrastructural examination. A recent
series showed that all patients undertaking genetic testing
harbored germline mutations, mostly in SDHB and rarely in SDHC.
The overall incidence of SDHB deﬁciency-associated RCC in unse-
lected renal tumors was estimated as being from 0.05% to 0.2%.24
Finally, RCCs involving translocation of anaplastic lymphoma
kinase (ALK) gene have been reported.11,25e27 The fusion partners
have been reported to be VCL,25 TPM3, or EML4 genes.26 Experience
with these emerging entities have been limited. There are still
controversies about whether they deserve to be regarded as
distinct entities or are variants of existing categories. The biological
behavior of these tumors is uncertain given the paucity of reported
cases. Further studies are required to clarify the nature of these
highly unusual tumors.
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